Other

COLISTIN: adult and paediatric guideline for South Africa, 2016

DOI: 10.1080/23120053.2016.1144285
Author(s): Quinten LabuschagneSouth African Society of Clinical Pharmacy (SASOCP), South Africa, Natalie SchellackSouth African Society of Clinical Pharmacy (SASOCP), South Africa, Andries GousSouth African Society of Clinical Pharmacy (SASOCP), South Africa, Elmien BronkhorstSouth African Society of Clinical Pharmacy (SASOCP), South Africa, Gustav SchellackSouth African Society of Clinical Pharmacy (SASOCP), South Africa, Lindie van TonderSouth African Society of Clinical Pharmacy (SASOCP), South Africa, Archele TruterSouth African Society of Clinical Pharmacy (SASOCP), South Africa, Caroline SmithSouth African Society of Clinical Pharmacy (SASOCP), South Africa, Ruth LancasterSouth African Society of Clinical Pharmacy (SASOCP), South Africa, Sonya KolmanSouth African Society of Clinical Pharmacy (SASOCP), South Africa,

Abstract

This document was created to serve as a guideline for colistin prescribing in South Africa. Antimicrobial resistance is threatening the effective prevention and treatment of a wide variety of infections, especially those that are caused by multi-drug-resistant (MDR) gram-negative bacteria. Colistin is typically used as salvage therapy, or last-line treatment, for MDR gram-negative infections. The dosing regimen should be optimised to be therapeutic and halt the emergence of resistance, whilst minimizing toxicity. This document provides evidence-based recommendations for adult and paediatric dosing, dosing in renal impairment, and the use of combination therapy to increase synergistic effects, as well as guidelines on the reconstitution and administration of colistin. This guideline is specifically aimed at healthcare workers who routinely treat patients with MDR gram-negative infections, especially in the intensive care setting.

Get new issue alerts for Southern African Journal of Infectious Diseases